HU221435B - Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production - Google Patents
Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production Download PDFInfo
- Publication number
- HU221435B HU221435B HU9800369A HUP9800369A HU221435B HU 221435 B HU221435 B HU 221435B HU 9800369 A HU9800369 A HU 9800369A HU P9800369 A HUP9800369 A HU P9800369A HU 221435 B HU221435 B HU 221435B
- Authority
- HU
- Hungary
- Prior art keywords
- weight
- potassium chloride
- coating
- coated
- particles
- Prior art date
Links
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 title claims abstract description 218
- 239000008188 pellet Substances 0.000 title claims abstract description 121
- 239000001103 potassium chloride Substances 0.000 title claims abstract description 108
- 235000011164 potassium chloride Nutrition 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims description 40
- 230000008569 process Effects 0.000 title claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title description 16
- 238000013270 controlled release Methods 0.000 title description 6
- 229960002816 potassium chloride Drugs 0.000 title 1
- 238000000576 coating method Methods 0.000 claims abstract description 90
- 239000011248 coating agent Substances 0.000 claims abstract description 87
- 239000002245 particle Substances 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 239000008187 granular material Substances 0.000 claims abstract description 29
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 239000002775 capsule Substances 0.000 claims abstract description 20
- 229920001577 copolymer Polymers 0.000 claims abstract description 18
- 239000000454 talc Substances 0.000 claims abstract description 18
- 229910052623 talc Inorganic materials 0.000 claims abstract description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 239000001828 Gelatine Substances 0.000 claims abstract description 8
- 229920000159 gelatin Polymers 0.000 claims abstract description 8
- 235000019322 gelatine Nutrition 0.000 claims abstract description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 6
- 239000006185 dispersion Substances 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 238000005243 fluidization Methods 0.000 claims description 17
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 15
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000975 dye Substances 0.000 claims description 11
- 239000008119 colloidal silica Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000007931 coated granule Substances 0.000 claims description 3
- 238000005453 pelletization Methods 0.000 claims description 3
- 238000005563 spheronization Methods 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- XPNLOZNCOBKRNJ-UHFFFAOYSA-N ethyl prop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C=C.COC(=O)C(C)=C XPNLOZNCOBKRNJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- 238000004898 kneading Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- -1 0.2-1 Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 239000004569 hydrophobicizing agent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 26
- 239000012153 distilled water Substances 0.000 description 23
- 238000004090 dissolution Methods 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 239000000839 emulsion Substances 0.000 description 15
- 239000013078 crystal Substances 0.000 description 14
- 229920001296 polysiloxane Polymers 0.000 description 12
- 239000002904 solvent Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 239000002994 raw material Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 5
- 229960003988 indigo carmine Drugs 0.000 description 5
- 239000004179 indigotine Substances 0.000 description 5
- 235000012738 indigotine Nutrition 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 229920004482 WACKER® Polymers 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000004815 dispersion polymer Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000000979 retarding effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 208000019025 Hypokalemia Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241001076195 Lampsilis ovata Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000008016 pharmaceutical coating Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 238000000710 polymer precipitation Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9800369A HU221435B (en) | 1998-02-20 | 1998-02-20 | Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production |
| PCT/HU1999/000013 WO1999042087A2 (en) | 1998-02-20 | 1999-02-19 | Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content |
| CZ20002858A CZ299182B6 (cs) | 1998-02-20 | 1999-02-19 | Vícedávková farmaceutická kompozice v tuhé perorální forme s rízeným uvolnováním, výhodne ve forme tablet nebo tvrdých želatinových kapslí s obsahem chloridu draselného |
| PL343268A PL193028B1 (pl) | 1998-02-20 | 1999-02-19 | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu chlorku potasu oparte na granulkach o wysokiej zawartości składnika aktywnego oraz sposób ich wytwarzania |
| AU25404/99A AU2540499A (en) | 1998-02-20 | 1999-02-19 | Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content |
| SK1188-2000A SK287281B6 (sk) | 1998-02-20 | 1999-02-19 | Viacdávková farmaceutická kompozícia v tuhej perorálnej forme s riadeným uvoľňovaním a spôsob jej prípravy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9800369A HU221435B (en) | 1998-02-20 | 1998-02-20 | Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU9800369D0 HU9800369D0 (en) | 1998-04-28 |
| HUP9800369A1 HUP9800369A1 (hu) | 2000-08-28 |
| HU221435B true HU221435B (en) | 2002-10-28 |
Family
ID=89996172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9800369A HU221435B (en) | 1998-02-20 | 1998-02-20 | Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production |
Country Status (6)
| Country | Link |
|---|---|
| AU (1) | AU2540499A (sk) |
| CZ (1) | CZ299182B6 (sk) |
| HU (1) | HU221435B (sk) |
| PL (1) | PL193028B1 (sk) |
| SK (1) | SK287281B6 (sk) |
| WO (1) | WO1999042087A2 (sk) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19928312A1 (de) * | 1999-06-16 | 2000-12-21 | Schering Ag | Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe |
| DE10347242A1 (de) * | 2003-10-10 | 2005-05-04 | Wella Ag | Farbstoffhaltige Pellets zum Färben von Keratinfasern |
| WO2007135470A1 (en) * | 2006-05-19 | 2007-11-29 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | Process for the preparation and surface coating of pellets |
| DE102008063800A1 (de) | 2008-12-19 | 2010-06-24 | Henkel Ag & Co. Kgaa | Beschichtete Färbemittel |
| CN102961363B (zh) * | 2012-12-14 | 2014-09-17 | 河南中帅医药科技股份有限公司 | 氯化钾缓释胶囊 |
| EP3213747B1 (en) | 2016-03-04 | 2019-02-13 | Laboratorio Reig Jofre S.A. | Tablets with a high-content of active ingredients useful for treating hair loss or stimulating its growth |
| EP4308286A1 (de) | 2021-03-16 | 2024-01-24 | Symrise AG | Wirkstoffkapseln |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0052075A1 (de) * | 1980-11-12 | 1982-05-19 | Ciba-Geigy Ag | Körnige Arzneimittel-Retardform |
| HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
| CH658188A5 (de) * | 1984-03-23 | 1986-10-31 | Ciba Geigy Ag | Lagerstabile schnellzerfallende pharmazeutische presslinge. |
| US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
-
1998
- 1998-02-20 HU HU9800369A patent/HU221435B/hu unknown
-
1999
- 1999-02-19 CZ CZ20002858A patent/CZ299182B6/cs not_active IP Right Cessation
- 1999-02-19 PL PL343268A patent/PL193028B1/pl unknown
- 1999-02-19 WO PCT/HU1999/000013 patent/WO1999042087A2/en active IP Right Grant
- 1999-02-19 SK SK1188-2000A patent/SK287281B6/sk not_active IP Right Cessation
- 1999-02-19 AU AU25404/99A patent/AU2540499A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9800369A1 (hu) | 2000-08-28 |
| WO1999042087A3 (en) | 1999-11-25 |
| HU9800369D0 (en) | 1998-04-28 |
| SK287281B6 (sk) | 2010-05-07 |
| WO1999042087A2 (en) | 1999-08-26 |
| SK11882000A3 (sk) | 2001-01-18 |
| CZ20002858A3 (cs) | 2001-01-17 |
| PL343268A1 (en) | 2001-08-13 |
| PL193028B1 (pl) | 2007-01-31 |
| CZ299182B6 (cs) | 2008-05-14 |
| AU2540499A (en) | 1999-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4728513A (en) | Granular delayed-release form of pharmaceutically active substances | |
| DE69832731T2 (de) | Arzneimittel mit magensaftresistentem überzug und methode zur herstellung | |
| CA2022640C (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
| US4900557A (en) | Pellet formulation | |
| US7790198B2 (en) | Preparation and administration form comprising an acid-labile active compound | |
| CA2310585C (en) | Novel administration form comprising an acid-labile active compound | |
| JPH0122245B2 (sk) | ||
| JPS5962520A (ja) | 徐放性薬学的錠剤とその製造方法 | |
| KR20000076475A (ko) | 약제학적 활성 성분의 함량이 90중량% 이하인 펠렛의제조방법 | |
| PT92616B (pt) | Processo para a preparacao de granulados para composicoes orais de particulas multiplas de libertacao controlada | |
| JPS629A (ja) | 持続放出性複合単位製剤 | |
| JP2000500477A (ja) | 即時放出型の薬学的組成物 | |
| UA82268C2 (uk) | Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення | |
| HU221435B (en) | Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production | |
| JP5042447B2 (ja) | 混合製剤 | |
| US20080113030A1 (en) | Sustained release tamsulosin formulations | |
| JPH04338323A (ja) | 放出制御製剤およびその製造法 | |
| CN101579524A (zh) | 一种掩味包衣组合物、包衣液及剂型 | |
| JPS63222112A (ja) | 徐放性顆粒 | |
| JPS62181214A (ja) | 徐放性粒状物の製造法 | |
| JP2008184393A (ja) | アクリルコポリマーとの混合粉砕による難水溶性薬物の溶解性改善及び放出制御型粒子の調製 | |
| JPH11209306A (ja) | 高薬物含有率徐放製剤の製法 | |
| TWI606846B (zh) | 製備藥物凝集體的方法 | |
| CA3034554A1 (en) | Formulations of cysteamine and cysteamine derivatives | |
| HU191102B (en) | Process for producing pharmaceutical compositions of regulated dissolution of the active agents containing water-soluble inorganic pharmacons |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: EGIS GYOGYSZERGYAR NYRT., HU Free format text: FORMER OWNER(S): EGIS GYOGYSZERGYAR RT., HU |